|Bid||1.79 x 800|
|Ask||110.00 x 1200|
|Day's Range||87.75 - 90.47|
|52 Week Range||86.71 - 121.23|
|Beta (3Y Monthly)||0.40|
|PE Ratio (TTM)||14.93|
|Earnings Date||Feb 5, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||101.16|
Taro Pharmaceutical Industries Ltd. (TARO) (“Taro” or the “Company”) announced today an explanation regarding taxation on the $500 million Special Dividend payable on December 28, 2018 to shareholders of record at the close of business on December 11, 2018. Following the announcement by the Company on November 5, 2018, that it will pay a $500 million dividend (the “Dividend”) on December 28, 2018, and in accordance with a specific tax ruling that the Company has received from the Israeli Tax Authority ("ITA"), the Company would like to elaborate about the procedures whereby Israeli taxes will be withheld from the Dividend payment, based on conditions set by the ITA in the tax ruling.
Taro (TARO) delivered earnings and revenue surprises of -18.37% and -5.03%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Haifa Bay, Israel-based company said it had profit of $1.60. The drug maker posted revenue of $159 million in the period. Taro shares have dropped nearly 6 percent since the beginning ...
We see how things are shaping up for the four pharma/biotech companies, which are scheduled to release second-quarter earnings on Nov 5.
Taro (TARO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
This article is intended for those of you who are at the beginning of your investing journey and want to learn about the link between company’s fundamentals and stock market Read More...
Todd Shriber’s pick for the contest is the ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO). The ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO), my choice for the InvestorPlace Best ETFs for 2018 competition, is enduring its worst quarter of 2018. With just a few trading days left in the third quarter, SBIO is sporting a quarter-to-date loss of 0.2%.
If you want to know who really controls Taro Pharmaceutical Industries Ltd (NYSE:TARO), then you’ll have to look at the makeup of its share registry. Institutions often own shares inRead More...
Taro Pharmaceutical (TARO) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
Taro (TARO) delivered earnings and revenue surprises of -26.61% and -13.88%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Haifa Bay, Israel-based company said it had profit of $1.71. The drug maker posted revenue of $154.6 million in the period. Taro shares have risen 7 percent since the beginning ...
Taro Pharmaceutical Industries Ltd. announced today that it plans to release its financial results for the quarter ended June 30, 2018, after the close of market on Thursday, August 9, 2018.
KemPharm (KMPH) presents positive top-line results on ADHD candidate KP415, which meets both primary and secondary endpoints in a pivotal study.
RedHill Biopharma (RDHL) announces allowances of two new patents from the United States Patent and Trademark Office and the European Patent Office for its Crohn's disease candidate, RHB-104.